Source comparison
MK-677 for Appetite: Research Application Comparison
Elderly muscle preservation 25mg/day oral +500–700 kcal/day Fat-free mass retention, grip strength 4–8 weeks Effective for reversing age-related anorexia; sustained appetite increase without tolerance development across 12+ months Post-surgical recovery 20–25m
This comparison does not assign a generated winner or score.
- Elderly muscle preservation
- 25mg/day oral
- +500–700 kcal/day
- Fat-free mass retention, grip strength
- 4–8 weeks
- Effective for reversing age-related anorexia; sustained appetite increase without tolerance development across 12+ months
- Post-surgical recovery
- 20–25mg/day oral
- +400–600 kcal/day
- Protein intake, nitrogen balance, wound healing markers
- 2–4 weeks
- Significant increase in protein consumption; accelerates positive nitrogen balance in catabolic states
- Cancer cachexia models
- +300–500 kcal/day
- Body weight stabilization, lean mass preservation
- 6–12 weeks
- Modest appetite improvement; less effective than direct ghrelin analogs but better tolerability profile
- Growth hormone deficiency
- +500–800 kcal/day
- IGF-1 normalization, body composition
- 8–16 weeks
- Dual benefit of GH elevation and appetite stimulation; insulin resistance risk requires monitoring
- Athletic performance research
- 10–25mg/day oral
- +300–600 kcal/day
- Training volume tolerance, recovery markers
- 4–12 weeks
- Appetite increase supports caloric surplus for hypertrophy phases; effect independent of training status
- The table demonstrates that MK-677 for appetite produces consistent caloric intake increases across diverse research populations, with the 25mg daily dose emerging as the standard in published literature. The effect manifests within days but reaches full magnitude by week 2–4 of continuous administration.